EQS-News: Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

05/17/2021 | 10:13pm
EQS-News / 18/05/2021 / 10:12 UTC+8 
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 
Inhibitor CB-708 (ATG-037) 
=-Antengene to lead development and commercialization of CD73 inhibitor CB-708 (ATG-037) worldwide 
=-Calithera will receive an upfront payment,potential milestones and tiered royalties 
SHANGHAI and SOUTH SAN FRANCISCO, U.S. May 17, 2021 (GLOBE NEWSWIRE) -- Antengene Corporation Limited ("Antengene", 
SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing 
global first-in-class and/or best-in-class therapeutics in hematology and oncology, and Calithera Biosciences, Inc. 
("Calithera", Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small 
molecule drugs for the treatment of cancer and other life-threatening diseases, today announced an exclusive, worldwide 
license agreement for the development and commercialization of CB-708 (ATG-037), Calithera's small molecule inhibitor 
of CD73. 
Under the terms of the license agreement, Calithera will receive an upfront payment and potential development, 
regulatory and sales milestones, and is eligible to receive tiered royalties on sales of the licensed product within 
the range of single to low double-digits. 
CD73 generates adenosine that is highly immunosuppressive. It enhances the proliferation of cancer cells through 
downregulation of IFN-?, NK cells, and CD8+ T cells. Tumors harness multiple CD73 mediated pathways to avoid an immune 
response.  Therefore, effective blockade of this target represents an ideal opportunity to restore immune competence in 
cancer patients, with strong potential to synergize with conventional therapies and other checkpoint inhibitors. CB-708 
is a highly potent, selective, orally-bioavailable inhibitor of CD73 that has great potential as either a monotherapy 
or in combination against a range of tumor types. 
Preclinical data presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting and the 2019 
Society for Immunotherapy of Cancer (SITC) Annual Meeting demonstrated that CB-708 has immune-mediated, single agent 
activity in syngeneic mouse tumor models. In preclinical studies, CB-708 was well-tolerated and showed enhanced 
anti-tumor activity when combined with either an anti-PD-L1 immunotherapy or with chemotherapeutic agents, such as 
oxaliplatin or doxorubicin. CB-708 has completed GLP toxicology studies and is poised to advance into clinical 
"We are excited to continue the advancement of CB-708 through our deep experience in global clinical development and 
extensive track record in commercialization in major markets around the world," said Dr. Jay Mei, Founder and Chief 
Executive Officer of Antengene. "CB-708 is a highly differentiated oral small molecule CD73 inhibitor with 
best-in-class potential due to its oral-bioavailability and high potency.  It overcomes the 'hook-effect'of clinical 
anti-CD73 antibodies and could completely block CD73 activity in vitro.  Antengene will continue to complete the GMP 
manufacturing of CB-708 and advance it into clinical trials for the treatment of multiple cancers including solid 
tumors and hematologic malignancies. This agreement brings a great addition to our portfolio of 12 assets with 
synergistic potential, is a testament to our abilities in accelerating global development, and represents another step 
in realizing our mission of treating patients beyond borders." 
"This agreement validates the capabilities of our drug discovery engine and represents a significant milestone for our 
CD73 program," said Susan Molineaux, PhD, president and chief executive officer of Calithera. "Antengene brings 
significant enthusiasm and proven global capabilities to the development and future commercialization of CB-708, a 
potential best-in-class oral small molecule CD73 inhibitor. This licensing agreement enables the continued advancement 
of this promising program, while allowing Calithera to focus our resources on our more advanced clinical programs 
evaluating telaglenastat in non-small cell lung cancer and CB-280 in cystic fibrosis." 
About Antengene 
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading clinical-stage R&D driven biopharmaceutical 
company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the 
most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since its establishment in 
2017, Antengene has built a broad and expanding pipeline of clinical and pre-clinical stage assets through partnerships 
as well as in-house drug discovery, and obtained 15 investigational new drug (IND) approvals and submitted 5 new drug 
applications (NDA) in multiple markets in Asia Pacific. Antengene's vision is to "Treat Patients Beyond Borders". 
Antengene is focused on and committed to addressing significant unmet medical needs by discovering, developing and 
commercializing first-in-class/best-in-class therapeutics. 
About Calithera Biosciences 
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of 
targeted therapies that disrupt cellular metabolic pathways to preferentially starve tumor cells and enhance 
immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people 
impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral 
therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San 
Francisco, California. 
Forward-looking statements 
The forward-looking statements made in this article relate only to the events or information as of the date on which 
the statements are made in this article. Except as required by law, we undertake no obligation to update or revise 
publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the 
date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this 
article completely and with the understanding that our actual future results or performance may be materially different 
from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors 
or our Company are made as of the date of this article. Any of these intentions may alter in light of future 
18/05/2021 Dissemination of a Marketing Press Release, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
Media archive at www.todayir.com
Image link: 

(END) Dow Jones Newswires

May 17, 2021 22:12 ET (02:12 GMT)

Copier lien
Latest news about "Companies"
22m ago
25m ago
1h ago
1h ago
1h ago